MedTrace Logo

Partners Demonstration Project of PrEP and ART

NCT02775929 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1013

Last updated 2017-12-08

No results posted yet for this study

Summary

The purpose of this protocol is to determine user preferences for antiretroviral therapy (ART) for HIV-1 infected partners and pre-exposure prophylaxis (PrEP) HIV-1 un-infected partners and to optimize targeted delivery and sustained use of these interventions.

Conditions

  • HIV Infection

Interventions

DRUG

FTC-TDF PrEP

FTC-TDF PrEP for HIV-1 uninfected partners

DRUG

ART

ART for HIV-1 infected partners

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • United States Agency for International Development (USAID)

    collaborator FED

  • University of Washington

    lead OTHER

Principal Investigators

  • Jared M Baeten, MD, PhD · University of Washington

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Kenya
  • Uganda

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02775929 on ClinicalTrials.gov